Gallen expert consensus, and the U.K. National Institute for Health and Clinical Excellence all recommend ais to lower the risk of tumour recurrence for postmenopausal women with early-stage hormone receptor–positive breast cancer 13–15. This evidence concerns the gene NR4A1 and breast cancer.